Increased expression of Filaggrin and Claudin-1 in the ocular surface of patients with atopic dermatitis

Imagem de Miniatura
Arquivos
art_CALLOU_Increased_expression_of_Filaggrin_and_Claudin1_in_the_2022.PDF (210.94 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
CALLOU, T. M. P.
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.36, n.2, p.247-254, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Atopic dermatitis (AD) is an itchy, chronic and inflammatory skin condition, with dysfunctional immune response and skin barrier defects. Reduction of filaggrin (FLG) and tight junctions (TJ) proteins, such as claudin-1 (CLDN-1), expression in cutaneous epithelial barrier is remarkable in AD pathogenesis. Ocular involvement occurs in approximately 40% of AD patients leading to changes in the structure of the conjunctiva. Objectives We aimed to evaluate the expression of FLG and CLDN-1 in the ocular surface of adults with AD, analysing bulbar conjunctival cells collected by a novel non-invasive cellular imprint. Methods Bulbar conjunctival epithelial cells were collected by cellular imprint technique, and FLG and CLDN-1 expression were assessed by immunofluorescence (IF) and real-time polymerase chain reaction (RT-PCR). Results We detected increased expression of FLG and CLDN-1, as well as their transcript levels in AD patients compared with healthy controls (HC). There was a positive correlation between tear film break-up time (TBUT) and FLG expression. Fluorescein staining was inversely associated with FLG expression. Conclusions Our results may reflect a reactive response of the ocular surface to AD-related ocular inflammation and associated dry eye disease. Further investigations focusing on the role of FLG and TJ expression in the ocular surface of AD patients may increment the understanding of the pathophysiology of extracutaneous AD and developing future targeted therapies.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/44635
Referências
  1. Akinlade B, 2019, BRIT J DERMATOL, V181, P459, DOI 10.1111/bjd.17869
  2. [Anonymous], 2016, Acta Med Croatica, V70, P125
  3. Batista DIS, 2015, J EUR ACAD DERMATOL, V29, P1091, DOI 10.1111/jdv.12753
  4. Beck KM, 2019, AM J CLIN DERMATOL, V20, P797, DOI 10.1007/s40257-019-00455-5
  5. Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049
  6. Bielory B, 2010, IMMUNOL ALLERGY CLIN, V30, P323, DOI 10.1016/j.iac.2010.06.004
  7. Bielory L, 2000, J ALLERGY CLIN IMMUN, V106, P1019, DOI 10.1067/mai.2000.111238
  8. Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011
  9. Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393
  10. Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619
  11. Contreras-Ruiz L, 2012, CURR EYE RES, V37, P971, DOI 10.3109/02713683.2012.700756
  12. De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018
  13. Dogan AS, 2016, CUTAN OCUL TOXICOL, V35, P315, DOI 10.3109/15569527.2015.1124887
  14. Dogru M, 1999, JPN J OPHTHALMOL, V43, P53, DOI 10.1016/S0021-5155(98)00061-6
  15. FEENSTRA RPG, 1992, OPHTHALMOLOGY, V99, P605
  16. Friedlaender MH, 1998, INT OPHTHALMOL CLIN, V38, P39, DOI 10.1097/00004397-199803840-00006
  17. Govind K, 2019, J ALLER CL IMM-PRACT, V7, P298, DOI 10.1016/j.jaip.2018.10.009
  18. Greisenegger EK, 2010, J EUR ACAD DERMATOL, V24, P607, DOI 10.1111/j.1468-3083.2009.03469.x
  19. Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021
  20. Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x
  21. HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44
  22. Hu Y, 2007, ALLERGY, V62, P917, DOI 10.1111/j.1398-9995.2007.01414.x
  23. Ibrahim OMA, 2014, CORNEA, V33, pS13, DOI 10.1097/ICO.0000000000000245
  24. Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040
  25. Ivert LU, 2019, ACTA DERM-VENEREOL, V99, P375, DOI 10.2340/00015555-3121
  26. Iwamoto S, 2012, BRIT J OPHTHALMOL, V96, P1272, DOI 10.1136/bjophthalmol-2012-301990
  27. Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041
  28. Kim J, 2019, ALLERGY ASTHMA PROC, V40, P84, DOI 10.2500/aap.2019.40.4202
  29. Kinoshita S, 2002, ADV EXP MED BIOL, V506, P641
  30. Kothari N, 2017, OSLI RETINA, V48, P513, DOI 10.3928/23258160-20170601-12
  31. KRENZER KL, 1994, ADV EXP MED BIOL, V350, P289
  32. Krenzer KL, 1997, INVEST OPHTH VIS SCI, V38, P142
  33. Lapp T, 2014, INT ARCH ALLERGY IMM, V163, P20, DOI 10.1159/000355965
  34. Lee SH, 2019, ANN DERMATOL, V31, P37, DOI 10.5021/ad.2019.31.1.37
  35. Leshem YA, 2015, BRIT J DERMATOL, V172, P1353, DOI 10.1111/bjd.13662
  36. Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564
  37. Lund ASK, 2012, OPEN OPHTHALMOL J, V6, P137, DOI 10.2174/1874364101206010137
  38. Maier P, 2017, OPHTHALMOLOGE, V114, P514, DOI 10.1007/s00347-017-0473-3
  39. Mancini AJ, 2008, PEDIATR DERMATOL, V25, P1, DOI 10.1111/j.1525-1470.2007.00572.x
  40. Mantelli F, 2013, CURR OPIN ALLERGY CL, V13, P563, DOI 10.1097/ACI.0b013e3283645899
  41. McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668
  42. Morita K, 2011, EUR J DERMATOL, V21, P12, DOI 10.1684/ejd.2010.1192
  43. Nakamura T, 2001, INVEST OPHTH VIS SCI, V42, P549
  44. Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009
  45. Orfali RL, 2017, GIORN ITAL DERMAT V, V152, P140, DOI 10.23736/S0392-0488.16.05533-4
  46. Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027
  47. Ozaki A, 2019, HISTOCHEM CELL BIOL, V151, P315, DOI 10.1007/s00418-018-1741-2
  48. Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767
  49. Patel N, 2018, CURR OPIN OPHTHALMOL, V29, P576, DOI 10.1097/ICU.0000000000000532
  50. Peyret-Lacombe A, 2007, CELL TISSUE RES, V328, P85, DOI 10.1007/s00441-006-0344-8
  51. Rabinowitz Y S, 1989, Refract Corneal Surg, V5, P400
  52. Santo RM, 2015, J CLIN EPIDEMIOL, V68, P370, DOI 10.1016/j.jclinepi.2014.07.009
  53. Siegfried EC, 2019, PEDIATR DERMATOL, V36, P172, DOI 10.1111/pde.13707
  54. Soria J, 2018, EXP EYE RES, V167, P31, DOI 10.1016/j.exer.2017.03.006
  55. Stahl JL, 2004, CURR OPIN ALLERGY CL, V4, P455, DOI 10.1097/00130832-200410000-00020
  56. Thyssen JP, 2017, J AM ACAD DERMATOL, V77, P280, DOI 10.1016/j.jaad.2017.03.003
  57. Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014
  58. Tong L, 2006, INVEST OPHTH VIS SCI, V47, P1938, DOI 10.1167/iovs.05-1129
  59. Toshino A, 2005, CURR EYE RES, V30, P731, DOI 10.1080/02713680591005940
  60. TUFT SJ, 1992, OPHTHALMOLOGY, V99, P180
  61. Utine CA, 2021, OCUL SURF, V19, P151, DOI 10.1016/j.jtos.2020.05.008
  62. VANBIJST.OP, 1969, ARCH OPHTHALMOL-CHIC, V82, P10
  63. Villegas BV, 2021, TURK OFTALMOL DERG, V51, P45, DOI 10.4274/tjo.galenos.2020.11456
  64. Wang GL, 2018, EXP EYE RES, V175, P199, DOI 10.1016/j.exer.2018.08.014
  65. Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z
  66. Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010
  67. Wollenberg A, 2020, J EUR ACAD DERMATOL, V34, P2717, DOI 10.1111/jdv.16892
  68. Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P657, DOI 10.1111/jdv.14891
  69. Wollenberg A, 2018, J ALLER CL IMM-PRACT, V6, P1778, DOI 10.1016/j.jaip.2018.01.034
  70. Yang EJ, 2019, PEDIATR DERMATOL, V36, P66, DOI 10.1111/pde.13727
  71. Yoshida Y, 2009, INVEST OPHTH VIS SCI, V50, P2103, DOI 10.1167/iovs.08-3046

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/33
Artigos e Materiais de Revistas Científicas - LIM/53
Carregar mais